Part 3: Beyond the Prescription Refill: The Role of the Pharmacist in Ongoing Monitoring of Patients with HBV
Premiere Date: Monday, September 27, 2021This activity offers CE credit for:
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, September 27, 2022
Note: Credit Is No Longer Available
 | Kimberly A. Forde, MD, PhD, MHS (Moderator) Associate Professor of Medicine Section of Hepatology, Department of Medicine Temple University Hospital, Lewis Katz School of Medicine Philadelphia, PA |
 | Lauren M. Hynicka, PharmD, BCPS Associate Professor of Pharmacotherapy University of Maryland School of Pharmacy Baltimore, MD |
Hepatocellular carcinoma (HCC) has the 8th highest mortality rate among cancers and viral hepatitis has driven a 38% increase in HCC in the US between 2003 and 2012. Indications for HCC surveillance includes all persons with cirrhosis, including persons who become HBsAg-positive, Asian or Black/African American males older than age 40, Asian females older than age 50, persons with a family history of HCC, and persons with a hepatitis D virus coinfection. One way to seize opportunities to educate patients about HCC is during their HBV medication refills.
The final installment in this CMEO webcast series on the role of pharmacists in improving HBV care focuses on utilizing interactions during medication refills to ask about regular monitoring and surveillance for HCC, heightening awareness of HBVr, querying patients receiving immunosuppression and about regular monitoring by their HCP, and advising patients to inform all current and future medical professionals of their HBsAg-positive status, especially if they ever need treatment for cancer or other immune disorders.
At the end of this CE activity, participants should be able to:
- Use interactions during HBV medication refills to counsel patients about routine monitoring for HCC and HBV reactivation.
Supported by an educational grant from Gilead Sciences, Inc.
Pharmacists
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .75 contact hours (0.075 CEUs) Universal Activity Number:
Enduring: JA0007185-0000-21-146-H01-P
Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Forde has no disclosures to report.
Dr. Hynicka has no disclosures to report.
Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
WCV-042-092721-47
